A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Subcutaneous Dose of UB-621 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs UB 621 (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions
- Sponsors United BioPharma
- 07 Feb 2017 Status changed from recruiting to completed.
- 14 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Nov 2015 Planned initiation date changed from 1 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.